Re: Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
|
1
|
Resverlogix Corp.
|
Dec 02, 2019 12:13PM
|
Re: Need a new computer, want to start some High Frequency Trading with RVX....
|
1
|
Resverlogix Corp.
|
Sep 07, 2017 12:15PM
|
Re: ESC TV at ESC Congress 2019 - The Daily Wrap-Up - Monday 2 September
|
1
|
Resverlogix Corp.
|
Sep 03, 2019 05:50AM
|
Re: Option(s)?
|
1
|
Resverlogix Corp.
|
Sep 15, 2020 04:14AM
|
Re: ESC Poster on BETonMACE Design and Baseline Data
|
1
|
Resverlogix Corp.
|
Sep 03, 2019 06:21AM
|
Re: New Zenith MD&A Posted on SEDAR
|
1
|
Zenith Epigenetics
|
Sep 29, 2017 01:18PM
|
Re: Resverlogix Closes Previously Announced $87 Million Private Placement with Shenzhen Hepalink
|
1
|
Resverlogix Corp.
|
Dec 04, 2017 01:45PM
|
Re: Warrants etc.
|
1
|
Resverlogix Corp.
|
Sep 25, 2019 07:06PM
|
Re: Top-Line, Primary Outcomes, Secondary Outcomes, Exploratory Outcomes, and Alzheimer's/Cognitio...
|
1
|
Resverlogix Corp.
|
Jul 13, 2018 01:50AM
|
Re: Hepa Links up close to the max 10% in early trading
|
1
|
Resverlogix Corp.
|
Apr 30, 2024 01:44PM
|
Re: (Newsfile Corp. - July 16, 2024)
|
1
|
Resverlogix Corp.
|
Jul 16, 2024 10:41AM
|
Re: Debt and 28 August
|
1
|
Resverlogix Corp.
|
Jul 27, 2017 10:25PM
|
Re: Cash burn and the cost of servicing the loan....
|
1
|
Resverlogix Corp.
|
Apr 16, 2018 02:57PM
|
Re: FDA news??
|
1
|
Resverlogix Corp.
|
Apr 01, 2017 03:25AM
|
Re: ... events section now updated... Where's the $$$ coming from
|
1
|
Resverlogix Corp.
|
Apr 01, 2017 03:30AM
|
Re: Games being played on the share price
|
1
|
Resverlogix Corp.
|
May 01, 2019 04:18PM
|
Re: Wondering?
|
1
|
Resverlogix Corp.
|
Apr 08, 2018 03:37PM
|
Re: "we are in now in the hands of the PI's running the trials"
|
1
|
Resverlogix Corp.
|
Oct 21, 2021 05:13PM
|
Re: Rough Transcript - Resverlogix Corporate Update and Conference Call - 06/10/2020
|
1
|
Resverlogix Corp.
|
Jun 11, 2020 01:48PM
|
Re: FXR and liver transaminase related adverse events
|
1
|
Resverlogix Corp.
|
Oct 03, 2018 12:10PM
|